(P1) EDAP TMS is strengthening its position in the urology market with new clinical data supporting its Focal One Robotic HIFU system, which demonstrated a 71% survival rate without androgen deprivation therapy at 30 months for radiorecurrent prostate cancer, a condition with few curative options.
(P2) "This large prospective multicenter study demonstrates that salvage HIFU can achieve clinically meaningful oncologic control while maintaining an acceptable safety profile in patients with localized recurrence after radiotherapy," said Dr. Guillaume Ploussard, first author of the HIFI-2 study published in European Urology Oncology.
(P3) The HIFI-2 study, the largest prospective trial in this setting, enrolled 531 patients across more than 30 centers. Key findings show a 71% androgen deprivation therapy-free survival (ADT-FS) at 30 months. For favorable subgroups, including patients with lower pre-HIFU PSA levels (≤4.5 ng/mL) and intermediate-risk disease, the ADT-FS rate reached as high as 84%. The study also noted low rates of severe complications and no significant deterioration in quality of life at 12 months.
(P4) The positive results could significantly expand the addressable market for EDAP's Focal One system, potentially driving higher revenue and boosting its stock. With Medicare and many commercial payors already providing coverage for the procedure, the HIFI-2 data provides compelling evidence for increased adoption by clinicians, solidifying the company's leadership in focal therapy for prostate conditions.
Historically, patients with prostate cancer recurrence after radiotherapy had limited treatment options beyond palliative care, which often comes with significant morbidity. The HIFI-2 study results position high-intensity focused ultrasound (HIFU) as a viable, organ-preserving alternative that offers a curative path while preserving quality of life. This shift could make Focal One a new standard of care for select patients.
"The publication of the HIFI-2 study marks an important milestone for the field of focal therapy and reinforces the clinical value of Focal One Robotic HIFU," said Ryan Rhodes, Chief Executive Officer of EDAP TMS. "The final results from this prospective multicenter study provide compelling evidence supporting Focal One as a non-invasive, organ-sparing, function-preserving option for patients facing recurrence after radiotherapy."
The successful HIFI-2 trial data arrives as the NCCN guidelines already recommend HIFU as a treatment option for patients with recurrence in the prostate. This existing recommendation, combined with established reimbursement channels, removes significant barriers to market access. For investors, this suggests a clearer path to revenue growth and market share gains for EDAP TMS in the competitive urology space, where it competes with other energy-based therapy providers. The company's focus on robotic, minimally invasive solutions aligns with broader trends in healthcare toward less invasive and more precise treatments.
This article is for informational purposes only and does not constitute investment advice.
